Yes, very convincing and detailed presentation, and I really like the depth and relavance of their BOD and Science Advisory Board. Looks like a very streamlined and cost effect approach for getting Proellex and Androxal a high probability for approval by FDA.
I still think the pricing between 11-12 is very attractive for a position. Sure beats DNDN at the moment, and the technicals are also attractive too!
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.